Research Studies

Nestle/Robarts

Initiation of induction of infliximab or adalimumab within the last 24 weeks

Active endoscopic disease

Pharmacosmos IDA

Must have IDA caused by different aetiologies* such as abnormal uterine bleed-ing, gastrointestinal diseases, cancer, bariatric procedures (gastric bypass operations), and other conditions leading to significant blood loss.

A documented history of intolerance to oral iron therapy for at least one month within 9 months prior to trial enrollment

Hb ≤ 10 g/dL

5. TSAT < 20 %

6. S-ferritin < 100 ng/mL

Prometheus Blood Draw and Optional Stool Collection

Pt must have been dx with IBD and be scheduled for a colonoscopy, excluded if the pt has received blood products in the last 3 months

Prometheus/Nestle for Moderate to Severe UC

Must be failing oral 5-ASA ≥2.4g/day, pt must not have been exposed to any other treatment in the last 8 weeks

GenFit, Intercept, Conatus, and Gilead NASH

Fibrosis stage 1-3

Gilead study enrolling compensated cirrhosis patients

Uncontrolled diabetes, Cirrhosis and other Chronic Liver Diseases excluded

Pt must be willing to have 2 liver Biopsies

Takeda Observational Study A For Crohn`s and UC

Initiated a biologic within 2 weeks of enrollment

Shire Eosinophilic Esophagitis

Histologic evidence of EOE

Non responsive to high dose PPI`s

Celgene, Janssen, Takeda, Gilead, Abbvie, Eli Lily and Genentech Crohn's

18 years or older

Moderate to severely active Crohn's disease

C - Diff Vaccine

50 years or older

At least 1 hospitalization > 2 nights in duration previous 12 month

At least 2 ER visits in the previous 12 months or

At least 10 outpatient visits in the previous 12 months

Residence in a skilled nursing facility or nursing home

Received systemic antibiotics at any time in the previous 12 weeks

No prior episodes of C-Diff

No bleeding disorders

No bowel resections

Abbvie, Genetech, Gilead, Takeda, and Protagonist - Moderate to Severe Ulcerative Colitis

18-80 years of age

Diagnosis of UC established at least 3-6 months prior to Day 1

Evidence of UC extending a minimum of 20 cm from the anal verge determine by baseline Endoscopy

Last Updated: May 2017

Please call (318) 525-3233 for more information.